DOCSLIB.ORG

Outcome of the Board Meeting August 6 2021

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Outcome of the Board Meeting August 6 2021 Ref: MHL/Sec&Legal/2021-22/34 Date: August 6, 2021 To, Head, Listing Compliance Department Head, Listing Compliance Department BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers Dalal Street, Exchange Plaza, Plot No. C/1. G Block, Mumbai - 400 001. Bandra -Kurla Complex, Bandra (East), Mumbai- 400051. Scrip Code: 542650 Scrip Symbol: METROPOLIS Subject: Outcome of the Board Meeting held on August 6, 2021 Reference: Regulation 30, 33 and 37 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Dear Sir/Madam, This is to inform you that the Board of Directors of the Company at their meeting held today have inter-alia: 1. Approved the Unaudited Standalone and Consolidated Financial Statements of the Company for the quarter ended June 30, 2021 and took note of the Limited Review Report issued by the Statutory Auditors on the Unaudited Standalone and Consolidated Financial Statements of the Company for the quarter ended June 30, 2021; The copy of the Unaudited Standalone & Consolidated Financial Statements of the Company as approved by the Board of Directors together with the Limited Review Report thereon for the quarter ended June 30, 2021 is enclosed as Annexure – 1. 2. Took note of the recommendation of the Audit Committee and subject to requisite consents / approvals, approved the Scheme of merger by absorption of Bokil Golwilkar Metropolis Healthcare Private Limited and Desai Metropolis Health Services Private Limited and Dr. Patel Metropolis Healthcare Private Limited and Lab One Metropolis Healthcare Services Private Limited and Micron Metropolis Healthcare Private Limited and R. V. Metropolis Diagnostic & Health Care Center Private Limited and Raj Metropolis Healthcare Private Limited and Sudharma Metropolis Health Services Private Limited (“Transferor Companies”) with the Company and their respective Shareholders (“Scheme”) under the provisions of sections 230 to 232 of the Companies Act, 2013; Brief details pertaining to the same as required under SEBI (LODR) Regulations, 2015 are enclosed as Annexure – 2. 3. Approved fund raise of up to Rs. 15,000 million by way of private placement or preferential issue or public issue or through any other permissible mode and/or combination thereof, including by way of qualified institutions placement, in accordance with applicable laws and subject to appropriate sanctions, permission and approvals including shareholders’ approval and statutory and regulatory approvals, as may be required; 4. Approved the Postal ballot Notice in terms of Section 110 of the Companies Act, 2013 read with Rules 20 and 22 of the Companies (Management and Administration) Rules, 2014 for seeking shareholders’ approval; BLOOD TESTS • DIAGNOSTICS • WELLNESS Metropolis Healthcare Limited Registered & Corporate Office: 250 D, Udyog Bhavan, Hind Cycle Marg, Worli, Mumbai - 400 030. CIN: L73100MH2000PLC192798 Tel No.: 8422 801 801 Email: [email protected] Website: www.metropolisindia.com Global Reference Laboratory: 4th Floor, Commercial Building-1A, Kohinoor Mall, Vidyavihar (W), Mumbai - 400 070. 5. Approved the acquisition of the balance Equity stake of 35% i.e. 10,50,000 Equity shares of Rs.10/- each in Metropolis Histoxpert Digital Services Private Limited (‘Histoxpert’) pursuant to a fresh valuation report issued by M/s. R.V. Shah & Associates, Chartered Accountants; Brief details pertaining to the acquisition as required under SEBI (LODR) Regulations, 2015 are enclosed as Annexure – 3. 6. Approved the appointment of Ms. Simmi Singh Bisht having Membership Number ACS 23360 as the Company Secretary and Compliance Officer of the Company (designated as Head - Legal and Secretarial) with effect from August 6, 2021 and took note of the cessation of Mr. Danish Allana as the Interim Compliance Officer of the Company with effect from August 6, 2021; Brief details pertaining to the same as required under SEBI (LODR) Regulations, 2015 are enclosed as Annexure – 4. 7. Authorized the Key Managerial Personnel of the Company to determine the materiality of events as prescribed under Regulation 30 (5) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015; Details of the Company officials are enclosed as Annexure – 5. The meeting commenced at 11:15 a.m. and concluded at 1:00 p.m. Thanking you, Yours faithfully For Metropolis Healthcare Limited Ameera Sushil Shah Managing Director DIN: 00208095 Encl. a/a BLOOD TESTS • DIAGNOSTICS • WELLNESS Metropolis Healthcare Limited Registered & Corporate Office: 250 D, Udyog Bhavan, Hind Cycle Marg, Worli, Mumbai - 400 030. CIN: L73100MH2000PLC192798 Tel No.: 8422 801 801 Email: [email protected] Website: www.metropolisindia.com Global Reference Laboratory: 4th Floor, Commercial Building-1A, Kohinoor Mall, Vidyavihar (W), Mumbai - 400 070. B S R & Co. LLP Chartered Accountants 14th Floor, Central B Wing and North C Wing, Telephone: +91 22 6257 1000 Nesco IT Park 4, Nesco Center, Fax: +91 22 6257 1010 Western Express Highway, Goregaon (East), Mumbai - 400 063 Limited Review Report on unaudited quarterly consolidated financial results of Metropolis Healthcare Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 To the Board of Directors Metropolis Healthcare Limited We have reviewed the accompanying Statement of unaudited consolidated financial results of Metropolis Healthcare Limited (“ the Parent”) and its subsidiaries (the Parent and its subsidiaries together referred to as “the Group”), and its share of the net profit after tax and total comprehensive income of its joint venture for the quarter ended 30 June 2021 (“the Statement”), being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended(‘Listing Regulations’). This Statement, which is the responsibility of the Parent’s management and approved by the Parent’s Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 “Interim Financial Reporting” (“Ind AS 34”), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 “Review of Interim Financial Information Performed by the Independent Auditor of the Entity”, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the Listing Regulations, to the extent applicable. The Statement includes the results of the following entities as stated- Sr No Name of Entity Relationship 1 Sudharma Metropolis Health Services Private Limited Subsidiary 2 Bokil Golwilkar Metropolis Healthcare Private Limited Subsidiary 3 Raj Metropolis Healthcare Private Limited Subsidiary 4 Desai Metropolis Health Services Private Limited Subsidiary 5 R.V. Metropolis Diagnostics & Healthcare Centre Private Limited Subsidiary 6 Micron Metropolis Healthcare Private Limited Subsidiary 7 Dr. Patel Metropolis Healthcare Private Limited Subsidiary 8 Lab One Metropolis Healthcare Services Private Limited Subsidiary 9 Amins Pathology Laboratory Private Limited Subsidiary Registered Office: B S R & Co. (a partnership firm with Registration No. BA61223) converted into B S R & Co. LLP (a Limited Liability Partnership with LLP Registration No. AAB-8181) with effect from October 14, 2013 14th Floor, Central B Wing and North C Wing, Nesco IT Park 4, Nesco Center, Western Express Highway, Goregaon (East), Mumbai - 400063 B S R & Co. LLP Limited Review Report on unaudited quarterly consolidated financial results of Metropolis Healthcare Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 (Continued) Metropolis Healthcare Limited 4. The Statement includes the results of the following entities as stated- (Continued) Sr No Name of Entity Relationship 10 Ekopath Metropolis Lab Services Private Limited Subsidiary 11 Metropolis Healthcare Lanka Private Limited Subsidiary 12 Metropolis Healthcare (Mauritius) Limited Subsidiary 13 Metropolis Star Lab Kenya Limited Subsidiary 14 Metropolis Healthcare Ghana Limited Subsidiary 15 Metropolis Bramser Lab Services (Mtius) Limited Subsidiary 16 Metropolis Healthcare (Tanzania) Limited Subsidiary 17 Metropolis Histoxpert Digital Services Private Limited Joint Venture Attention is drawn to the fact that the figures for the 3 months ended 31 March 2021 as reported in these financial results are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures
Load more

Recommended publications
  • Separate Financial Statements Fiscal Year 2019
    201Separate financial9 statements PPorscheorsche TaycanTaycan TurboTurbo S 3 Content Group management report and management report of Porsche Automobil Holding SE 6 Fundamental information about the group 10 Report on economic position 12 Significant events and developments at the Porsche SE Group 12 Significant events and developments at the Volkswagen Group 20 Business development 24 Results of operations, financial position and net assets 31 Porsche Automobil Holding SE (financial statements pursuant to the German Commercial Code) 37 Sustainable value enhancement in the Porsche SE Group 41 Overall statement on the economic situation of Porsche SE and the Porsche SE Group 43 Remuneration report 44 Opportunities and risks of future development 52 Publication of the declaration of compliance and corporate governance report 78 Subsequent events 79 Forecast report and outlook 80 Glossary 85 4 Financials 86 Balance sheet of Porsche Automobil Holding SE 90 Income statement of Porsche Automobil Holding SE 91 Notes to the consolidated fi nancial statements 92 Independent auditor’s report 212 Responsibility statement 220 5 VVolkswagenolkswagen IID.3D.3 6 1 Group management report and management report of Porsche Automobil Holding SE 7 8 Group management report and management report of Porsche Automobil Holding SE 6 Fundamental information about the group 10 Report on economic position 12 Significant events and developments at the Porsche SE Group 12 Significant events and developments at the Volkswagen Group 20 Business development 24 Results
    [Show full text]
  • Blood Tests • Diagnostics • Wellness
    Ref: MHL/Sec&Legal/2020-21/138 Date: October 1, 2020 To, Head, Listing Compliance Department Head Listing Compliance Department BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers Dalal Street, Exchange Plaza, Plot No. C/1. G Block, Mumbai - 400 001. Bandra -Kurla Complex, Bandra (East), Mumbai- 400051 Scrip Code: 542650 Scrip Symbol: METROPOLIS Sub: Intimation of Credit Rating. Dear Sir/Madam, Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, we wish to inform you that CRISIL, a Credit Rating Agency has reaffirmed its ‘CRISIL AA-/Stable’ rating on the Non-Convertible Debentures and the long-term loan facility of the Company and has also reassigned its ‘CRISIL A1+’ rating to the short-term bank facility of the Company. Further, please note that the Company has neither issued the Non-Convertible Debentures nor availed the long-term or short-term bank facility as aforesaid till date. The rating rationale dated September 30, 2020 received from CRISIL on October 1, 2020 and accepted by the Company is enclosed herewith for your kind reference. The above is for your information and records. Yours Faithfully For Metropolis Healthcare Limited Poonam Tanwani Company Secretary & Compliance Officer Membership No. A19182 Encl. a/a BLOOD TESTS • DIAGNOSTICS • WELLNESS Metropolis Healthcare Limited Registered & Corporate Office: 250 D, Udyog Bhavan, Hind Cycle Marg, Worli, Mumbai - 400 030. CIN: L73100MH2000PLC192798 Tel No.: 8422 801 801 Email: [email protected]
    [Show full text]
  • Download PDF, 19 Pages, 505.25 KB
    VOLKSWAGEN AKTIENGESELLSCHAFT Shareholdings of Volkswagen AG and the Volkswagen Group in accordance with sections 285 and 313 of the HGB and presentation of the companies included in Volkswagen's consolidated financial statements in accordance with IFRS 12 as of 31.12.2019 Exchange rate VW AG 's interest Equity Profit/loss (1€ =) in capital in % in thousands, in thousands, Name and domicile of company Currency Dec. 31, 2019 Direct Indirect Total local currency local currency Footnote Year I. PARENT COMPANY VOLKSWAGEN AG, Wolfsburg II. SUBSIDIARIES A. Consolidated companies 1. Germany ASB Autohaus Berlin GmbH, Berlin EUR - 100.00 100.00 16,272 1,415 2018 AUDI AG, Ingolstadt EUR 99.64 - 99.64 13,701,699 - 1) 2019 Audi Berlin GmbH, Berlin EUR - 100.00 100.00 9,971 - 1) 2018 Audi Electronics Venture GmbH, Gaimersheim EUR - 100.00 100.00 60,968 - 1) 2019 Audi Frankfurt GmbH, Frankfurt am Main EUR - 100.00 100.00 8,477 - 1) 2018 Audi Hamburg GmbH, Hamburg EUR - 100.00 100.00 13,425 - 1) 2018 Audi Hannover GmbH, Hanover EUR - 100.00 100.00 16,621 - 1) 2018 AUDI Immobilien GmbH & Co. KG, Ingolstadt EUR - 100.00 100.00 82,470 3,399 2019 AUDI Immobilien Verwaltung GmbH, Ingolstadt EUR - 100.00 100.00 114,355 1,553 2019 Audi Leipzig GmbH, Leipzig EUR - 100.00 100.00 9,525 - 1) 2018 Audi München GmbH, Munich EUR - 100.00 100.00 270 - 1) 2018 Audi Real Estate GmbH, Ingolstadt EUR - 100.00 100.00 9,859 4,073 2019 Audi Sport GmbH, Neckarsulm EUR - 100.00 100.00 100 - 1) 2019 Audi Stuttgart GmbH, Stuttgart EUR - 100.00 100.00 6,677 - 1) 2018 Auto & Service PIA GmbH, Munich EUR - 100.00 100.00 19,895 - 1) 2018 Autonomous Intelligent Driving GmbH, Munich EUR - 100.00 100.00 250 - 1) 2018 Autostadt GmbH, Wolfsburg EUR 100.00 - 100.00 50 - 1) 2018 B.
    [Show full text]
  • Intimation of Annual Report and AGM Notice 2020
    Ref: MHL/Sec&Legal/2021-22/29 Date: July 18, 2021 To, Head, Listing Compliance Department Head, Listing Compliance Department BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers Exchange Plaza, Plot No. C/1. G Block, Dalal Street, Mumbai - 400 001. Bandra -Kurla Complex, Bandra (East), Mumbai- 400051. Scrip Code: 542650 Scrip Symbol: METROPOLIS Sub: Copy of Annual Report of the Company for the Financial Year 2020-2021 along with the Notice convening the 21st Annual General Meeting Ref: Our earlier letter dated July 05, 2021 having reference no. MHL/Sec&Legal/2021-22/23 Dear Sir/Madam, With reference to the captioned subject, our earlier letter dated July 05, 2021 having reference no. MHL/Sec&Legal/2021-22/23 wherein we had informed the Exchange about the 21st Annual General Meeting (‘AGM’) of the Company. In continuation to the same and as required under Regulations 30 and 34 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we submit herewith the Annual Report of the Company for the Financial Year 2020-2021 along with the Notice convening the 21st AGM of the Company scheduled to be held on Wednesday, August 11, 2021 at 9.30 A.M. (IST) through Video Conferencing / Other Audio Visual Means (‘VC / OAVM’) in compliance with the General Circular No. May 05, 2020 read with Circulars dated April 08,2020, April 13, 2020 and January 13, 2021 issued by the Ministry Corporate Affairs and Circular dated May 12,2020 and January 15, 2021 issued by the Securities and Exchange Board of India.
    [Show full text]
  • Blood Tests • Diagnostics • Wellness
    Ref: MHL/Sec&Legal/2020-21/130 Date: August 24, 2020 To, Head, Listing Compliance Department Head Listing Compliance Department BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers Dalal Street, Exchange Plaza, Plot No. C/1. G Block, Mumbai - 400 001. Bandra -Kurla Complex, Bandra (East), Mumbai- 400051. Scrip Code: 542650 Scrip Symbol: METROPOLIS Subject: Copy of Annual Report of the Company for the Financial Year 2019-2020 along with the Notice convening the 20th Annual General Meeting Ref.: Our earlier letter dated August 19, 2020 having reference no. MHL/Sec&Legal/2020-21/128 Dear Sir/Madam, With reference to the captioned subject, our earlier letter dated August 19, 2020 having reference no. MHL/Sec&Legal/2020-21/128 wherein we had informed the Exchange about the 20th Annual General Meeting (‘AGM’) of the Company. In continuation to the same and as required under Regulations 30, 34 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we submit herewith the Annual Report of the Company for the Financial Year 2019-2020 along with the Notice convening the 20th AGM of the Company scheduled to be held on Wednesday, September 16, 2020 at 9.00 A.M. (IST) through Video Conferencing / Other Audio Visual Means (‘VC / OAVM’) in compliance with the General Circular No. 14/ 2020 dated April 08,2020, General Circular No. 17 /2020 dated April 13, 2020, General Circular No. 20/2020 dated May 05,2020 issued by Ministry Corporate Affairs and Circular No. SEBI/HO/CFD/CMD1/CIR/P/2020/79 dated May 12,2020 issued by SEBI.
    [Show full text]
  • Outcome of Board Meeting Held on 27.05.2021
    Ref: MHL/Sec&Legal/2021-21/9 Date: May 27, 2021 To, Head, Listing Compliance Department Head, Listing Compliance Department BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers Dalal Street, Exchange Plaza, Plot No. C/1. G Block, Mumbai - 400 001. Bandra -Kurla Complex, Bandra (East), Mumbai- 400051. Scrip Code: 542650 Scrip Symbol: METROPOLIS Sub: Outcome of Board Meeting Reference: Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. (‘LODR’) Dear Sir/ Madam, This is to inform you that the Board of Directors of the Company at their meeting held today have inter-alia: 1. Approved the Standalone and Consolidated Financial Statements of the Company for the quarter and year ended March 31, 2021. The Audited Standalone and Consolidated Financial Statements of the Company as approved together with the Auditor’s Report thereon for the quarter and year ended March 31, 2021 are enclosed as Annexure 1. Further, pursuant to the provisions of Regulation 33 (3) (d) of the SEBI LODR, the declaration of Unmodified Opinion by the Managing Director of the Company, in respect of the Audited Standalone and Consolidated Financial Statements of the Company for the year ended March 31, 2021 is enclosed as Annexure 2. 2. Approved the appointment of Mr. Hemant Sachdev as an Additional Non-Executive Non- Independent Director of the Company, who shall hold office till the date of the forthcoming Annual General Meeting and shall continue to hold office thereafter, subject to the approval of the members of the Company at the forthcoming Annual General Meeting.
    [Show full text]
  • Porsche SE 2020 Financial Statements
    Financial statements 20202020 Note on the combined management report The management report of Porsche Automobil Holding SE and the group management report are combined and published in the Porsche Automobil Holding SE Annual Report 2020. The separate financial statements and the management report, which is combined with the group management report, of Porsche Automobil Holding SE for the fiscal year 2020 are submitted to the operator of the elektronischer Bundesanzeiger (Electronic German Federal Gazette) and are available on the website of the Company Register. In addition to this, the separate financial statements and the annual report including the combined management report of Porsche Automobil Holding SE are available on the homepage of Porsche Automobil Holding SE at www.porsche-se.com/en/investor-relations/financial-publications. 3 4 Financial statements 5 6 Content Balance sheet of Porsche Automobil Holding SE 8 Income statement of Porsche Automobil Holding SE 9 Notes to the financial statements 10 Independent auditor’s report 135 Responsibility statement 145 7 2 2 Balance sheet of Porsche Automobil Holding SE as of 31 December 2020 Balance sheet of Porsche Automobil Holding SE as of 31 December 2020 Note 31/12/2019 € thousand 31/12/2020 € thousand Note 31/12/2020 31/12/2019 Assets Assets Fixed assets [1] IntangibleFixed assets assets [1] 294 392 Property,Intangible plantassets and equipment 105294 142392 FinancialProperty, assetsplant and equipment 22,944,506105 22,960,669142 Financial assets 22,944,90522,944,506 22,961,20422,960,669
    [Show full text]
  • PE/VC Agenda
    PE/VC Agenda India Trend Book 2020 08 32 Investment activity: highlights Sector insights and trends 44 52 Exits show a lukewarm Spotlight: importance of PE/ performance VC investments as a source of FDI 56 66 The evolving tax and Glossary of acronyms regulatory framework Contents 68 Appendices Foreword Padmanabh Sinha Chairman, IVCA Managing Partner, TATA Opportunities Fund Despite headwinds originating from global trade, geo- The PE/VC industry contributes very significantly to political factors and significant domestic concerns over productive capital formation, very aptly highlighted credit availability and slowdown in growth, the Indian in the Spotlight section of this report, with productive PE/VC industry has continued to repose its faith in capital formation being more than 3/4th of aggregate the ‘India story’, investing a record high for the third PE/VC investment (data over the last three years). year in a row. At US$48 billion (in aggregate including The PE/VC industry is thus a pillar of strength in the infrastructure, real estate, PIPE and credit investments), Indian economy and is leading the charge towards Indian PE/VC investments grew by 28% y-o-y in 2019. ‘democratization of entrepreneurship’. It is playing a meaningful role in helping solve some of the problems As the Indian PE/VC sector moves towards global norms, facing the country today and is providing the right its growth has been deep and spread across most asset momentum to the Indian economy where the companies classes and deal types. Some of the highlights are: backed by them are championing innovation, creating • Buyouts grew by ~56% to notch up over US$16 new jobs, mentoring new entrepreneurs and bringing billion of PE/VC investments in 2019 the right solutions to help promote financial inclusion, build better infrastructure, increase renewable energy • Start-up investments grew by 22% to US$7.9 billion and promote capital efficiency in the Indian economy.
    [Show full text]
  • Full Annual Report
    ANNUAL REPORT 2019-20 TRANSFORMING FOR A NEW TOMORROW ACROSS THE PAGES 01-32 CORPORATE OVERVIEW 33-109 Transforming for a New Tomorrow 01 STATUTORY REPORTS Our Approach to Reporting 02 Metropolis at a Glance 04 Management Discussion and 33 COVID-19 Highlights 06 Analysis Report Chairman’s Message 08 Board’s Report 38 Letter from MD’s Desk 10 Corporate Governance 78 Business Model 12 Business Responsibility Report 103 Financial capital 14 Service capital 16 TRANSFORMING FOR A NEW Intellectual capital 18 Human capital 20 TOMORROW Relationship capital 22 110-255 Natural Capital 24 FINANCIAL STATEMENTS Board of Directors 26 A crossroad is an opportunity to redefi ne our choices while making a Leadership Team 29 Standalone 110 shift in our perspective. For the last few months, healthcare institutions Awards & Recognition 30 Consolidated 180 in India have been found at the forefront of a challenging situation. The Corporate Information 32 sudden outbreak of COVID-19 pandemic has brought everyone to a point of transformation. We, at Metropolis Healthcare Limited (‘Metropolis’ or ‘the Company’), promptly responded to this stimulus by adapting to the change. We transformed and adapted not to cope up, but to win. We redesigned to Please fi nd our online version at Investor information quickly merge with the change, transforming ourselves for a https://www.metropolisindia.com/about-metropolis/investors/ BSE Code 542650 new tomorrow. NSE Symbol METROPOLIS Or simply scan to download The current scenario foretells two changes for the pathology industry: Bloomberg Code METROHL:IN Consolidation of path labs in the nation and consumers’ keen interest in AGM Date Wednesday, 16th September 2020 good health and overall wellness.
    [Show full text]
  • PE/VC Agenda
    PE/VC Agenda India Trend Book 2021 PE/VC Agenda: India Trend Book 2021 Page 1 Foreword ..................................................................... 3 Preface and outlook ..................................................... 4 A brief review of 2020 .................................................. 9 PE/VC in India – a decade in review ............................. 15 2011-2020: key trends .............................................. 27 Analysis of sectoral performance – 2011-2020 ............ 49 Exits – a mixed bag ..................................................... 63 Trends for the next decade ......................................... 75 Tax and regulatory updates ........................................ 77 Glossary of acronyms ................................................. 90 Appendices ................................................................ 92 Foreword Renuka Ramnath Chairperson, IVCA Founder, Managing Director & CEO, Multiples Alternate Asset Management Pvt. Ltd. 2020 was a remarkable year; a year that can be deemed as Investor confidence in India is a combination of long-term the year of digital acceleration. The pandemic and its growth opportunities, a robust business infrastructure and aftermath literally brought the planet to a standstill for some supportive government and regulatory measures and time, disrupting economic and social activity in ways never reforms. seen before. It was a year that saw PE/VC investment activity start off on a sombre note, then plunge sharply in 2Q- Today, the Indian PE/VC industry is an important part of the 3Q2020, only to recover smartly in 4Q2020. It was a year Indian economy. It is the single largest source of much that saw the Reliance Group entities successfully pull off the needed FDI. The industry is not just a provider of capital, but largest private fund-raising exercise across their Jio and also an agent of change, that is playing an important role in Retail platforms, attracting several marquee global investors providing the right momentum to the Indian economy.
    [Show full text]
  • Major Categories
    AWARDS DINNER CEREMONY │ S eptember 23, 2010, India FINALIST TOP CONTENDERS ANNOUNCEMENT August 27, 2010 New York, NY: GOLD STANDARD of PERFORMANCE, the ASIA-PACIFIC M&A ATLAS AWARDS honors top deals, dealmakers and firms from the greater Asia Pacific including India, China, South East Asia, Far East and the Australia/Oceanic mergers, acquisitions, private equity and venture capital communities. HONORARY GUEST EVENING REMARKS by: Paul A. Folmsbee, Consul General American Consulate General, State Department of United States of America WINNERS are revealed for the first time at the awards gala ceremony held September 23, 2010. Nominees or their representatives must confirm “proof of attendance” for the WINNER SELECTION process and be in attendance at the awards gala ceremony to be honored. Selection criteria are based on transaction performance metrics such as deal novelty and structure; sector and markets, jurisdictional intricacies; professional leadership; brand strength; resourcefulness; and other criteria. ENQUIRIES, contact: Raj Kashyap, at [email protected] or +914.886.3085. CONGRATULATIONS to the TOP CONTENDER FINALISTS CIRCLE MAJOR AWARD CATEGORIES: (Winner Selection Policy: Nominees must confirm “proof of attendance” by September 12 for inclusion in the winner selection process. Winners are honored and presented with a trophy.) ASIA PACIFIC M&A DEAL of the YEAR │ above 500 million USD (Qualification: Transaction private equity or corporate; cross-border, domestic, any sector, below a billion USD in size) • AsiaInfo Holdings, Inc. merger with Linkage Technologies International Holdings Limited. The Hina Group, BofA Merrill Lynch, Barclays Capital • Doosan Heavy Industries & Construction acquisition of Skoda Power. Citigroup • CVC Capital Partners control acquisition in PT Matahari Putra Prima Tbk, CVC Asia • Fortis Healthcare strategic acquisition stake in Parkway Holdings Ltd from TPG Capital.
    [Show full text]
  • DIAGNOVISION Products Corporation B-5, 2Nd Floor, Street No : 13, Madhu Vihar, Patparganj, Delhi - 110 092 Phones: +91-11-2223 6107, Fax : + 91-11-2223 4058
    DIAGNOVISION Products Corporation B-5, 2nd Floor, Street No : 13, Madhu Vihar, Patparganj, Delhi - 110 092 Phones: +91-11-2223 6107, Fax : + 91-11-2223 4058. Mobile: +91-98102 69754 /9555808205 Email: [email protected], [email protected], Website : www.diagno-vision.com, www.diagnovision.in Blood Drawing Chair - USER LIST Total Chair Installed: 166 Model Customer Name CITY Country/State Quantity BDC-20 Quality Lab Inc QATAR 5 BDC-30 Quality Lab Inc QATAR 5 BDC-20 Kamayani Bajaj Hospital Pune MAHARASTRA 2 BDC-30 Mahaa Diagnostics Hyderabad TELENGANA 2 BDC-30 Thyrocare Franchise Delhi DELHI 1 BDC-30 Bimla Medicos Ambala HARYANA 1 BDC-30 Nischal Enterprises Pune MAHARASTRA 1 BDC-20 Tata Hospital Jamshedpur JHARKHAND 3 BDC-30 Sahara Agency Bhopal MADHYA PRADESH 1 BDC-30 Lanka Hospital Diagnostics Colombo SRI LANKA 3 BDC-20 Malabar Diagnostics Kozikode KERALA 3 BDC-30 Durgapur Diagnostics Durgapur WEST BENGAL 2 BDC-10 Silverline Hospital Cochin KERALA 1 BDC-10 Bharat Tiwari Jaipur RAJASTHAN 1 BDC-10 Suraksha Diagnostics Noida UTTAR PRADESH 1 BDC-20 Divine Nursing Home Kolkata WEST BENGAL 1 BDC-20 Mallya Distributors Manipal KARNATAKA 1 BDC-10 Mallya Distributors Manipal KARNATAKA 5 BDC-30 Biocell Diagnostics Srinagar JAMMU KASHMIR 1 BDC-30 Emeditek Gurgaon HARYANA 1 BDC-30 Era Medical College Lucknow UTTAR PRADESH 1 BDC-Vena Metropolis Lab KENYA 6 BDC-Vena Kashmir Health Services Srinagar JAMMU KASHMIR 5 BDC-Vena Kare Hospital, Punchkula HARYANA 1 BDC-20 Dr Bhatt's Lab, Rajkot GUJARAT 1 BDC MEDILINE Respirotech Delhi DELHI 3 BDC-30 K.K.
    [Show full text]